We are also interested in the study of the roles of caspase - 2 in host responses induced by other vaccines (e.g.,
tuberculosis vaccine BCG).
Studies in several countries have demonstrated that
the tuberculosis vaccine BCG, when given early in life, confers some protection against acute leukaemia (Journal of the Royal Society of Medicine, vol 96, p 389).
Not exact matches
The study, «The efficacy of the
BCG vaccine against newly emerging clinical strains of Mycobacterium
tuberculosis,» was published in the journal PLOS One in September.
Orme and his research team in Fort Collins investigated whether the existing
vaccine for TB, which goes by the acronym
BCG (bacille Calmette - Guerin), worked equally well against different clinical strains of
tuberculosis.
Less than 5 per cent of the world's children are fully immunised when you add
BCG (for
tuberculosis), measles, rubella, polio, hepatitis B (hep B), Haemophilus influenzae type B (Hib), pneumococcal and rotavirus
vaccines.
Although the immune mechanisms implicated in the development of childhood asthma are not fully understood, some studies seem to suggest that the
BCG vaccine, used in
tuberculosis prevention, may have a protective effect on childhood asthma.
And the
BCG vaccine against
tuberculosis can stimulate this memory.
Shortly after the introduction of the
BCG vaccine it was noticed that not only
tuberculosis occurred less frequently but that young children also died less due to other pathogens.
An earlier form of the
vaccine was used in the DarDar Trial, a seven - year study in Tanzania sponsored by the U.S. National Institutes of Health involving patients with HIV infection who at birth had received
BCG, the current
tuberculosis vaccine.
BCG, a
vaccine against
tuberculosis, was discovered in the 1920s and is one of the most used
vaccines worldwide.
«Taken together, these two studies suggest that the new scalable
vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB
vaccine in humans since
BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the
Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.
The study, «The efficacy of the
BCG vaccine against newly emerging clinical strains of Mycobacterium
tuberculosis,» was published in September.
Research Focus: My research project focuses on the T cell response of mycobacterium
tuberculosis to further understand how the current
BCG vaccine can be improved.